Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease.


Journal

American journal of hypertension
ISSN: 1941-7225
Titre abrégé: Am J Hypertens
Pays: United States
ID NLM: 8803676

Informations de publication

Date de publication:
03 11 2020
Historique:
received: 30 04 2020
revised: 03 06 2020
accepted: 09 06 2020
pubmed: 13 6 2020
medline: 21 9 2021
entrez: 13 6 2020
Statut: ppublish

Résumé

Our aims were to assess whether arterial stiffness is associated with a higher risk for kidney dysfunction among persons without chronic kidney disease (CKD). We analyzed data from the national health checkup system in Japan; for our analyses, we selected records of individuals who completed assessments of cardio-ankle vascular index (CAVI) and kidney function from 2005 to 2016. We excluded participants who had CKD at baseline, defined as the presence of proteinuria or estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2. We compared 2 groups of CAVI measurements-the highest quartile (≧8.1) and the combined lower 3 quartiles (<8.1). We used Cox proportional hazards models to assess associations between these 2 groups and subsequent CKD events, proteinuria, eGFR <60 ml/min/1.73 m2, and rapid eGFR decline (greater than or equal to -3 ml/min/1.73 m2 per year). The mean age of the 24,297 included participants was 46.2 years, and 60% were female. Over a mean follow-up of 3.1 years, 1,435 CKD events occurred. In a multivariable analysis, the hazard ratios with 95% confidence intervals (CIs) for the highest vs. combined lower quartiles of CAVI measurements were 1.3 (1.1, 1.5) for CKD events, 1.3 (0.96, 1.62) for proteinuria, 1.4 (1.1, 1.7) for eGFR <60 ml/min/1.73 m2, and the odds ratio with 95% CI was 1.3 (1.1, 1.4) for rapid eGFR decline. Persons with CAVI measurements ≧8.1 had a higher risk for CKD events compared with their counterparts with CAVI measurements <8.1. Greater arterial stiffness among adults without CKD may be associated with kidney dysfunction.

Sections du résumé

BACKGROUND
Our aims were to assess whether arterial stiffness is associated with a higher risk for kidney dysfunction among persons without chronic kidney disease (CKD).
METHODS
We analyzed data from the national health checkup system in Japan; for our analyses, we selected records of individuals who completed assessments of cardio-ankle vascular index (CAVI) and kidney function from 2005 to 2016. We excluded participants who had CKD at baseline, defined as the presence of proteinuria or estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2. We compared 2 groups of CAVI measurements-the highest quartile (≧8.1) and the combined lower 3 quartiles (<8.1). We used Cox proportional hazards models to assess associations between these 2 groups and subsequent CKD events, proteinuria, eGFR <60 ml/min/1.73 m2, and rapid eGFR decline (greater than or equal to -3 ml/min/1.73 m2 per year).
RESULTS
The mean age of the 24,297 included participants was 46.2 years, and 60% were female. Over a mean follow-up of 3.1 years, 1,435 CKD events occurred. In a multivariable analysis, the hazard ratios with 95% confidence intervals (CIs) for the highest vs. combined lower quartiles of CAVI measurements were 1.3 (1.1, 1.5) for CKD events, 1.3 (0.96, 1.62) for proteinuria, 1.4 (1.1, 1.7) for eGFR <60 ml/min/1.73 m2, and the odds ratio with 95% CI was 1.3 (1.1, 1.4) for rapid eGFR decline.
CONCLUSIONS
Persons with CAVI measurements ≧8.1 had a higher risk for CKD events compared with their counterparts with CAVI measurements <8.1. Greater arterial stiffness among adults without CKD may be associated with kidney dysfunction.

Identifiants

pubmed: 32530466
pii: 5856532
doi: 10.1093/ajh/hpaa097
pmc: PMC7750955
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1003-1010

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd.

Références

Hypertension. 2010 May;55(5):1110-5
pubmed: 20212269
Hypertens Res. 2011 Jun;34(6):779-83
pubmed: 21471974
Hypertension. 2011 Nov;58(5):839-46
pubmed: 21968753
Hypertension. 2019 Jan;73(1):75-83
pubmed: 30571549
Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2190-7
pubmed: 26563380
J Clin Hypertens (Greenwich). 2019 Jan;21(1):16-24
pubmed: 30456903
Hypertens Res. 2009 Feb;32(2):115-21
pubmed: 19262469
Atherosclerosis. 2010 Sep;212(1):345-50
pubmed: 20594557
Hypertension. 2018 Jun;71(6):1101-1107
pubmed: 29712736
J Atheroscler Thromb. 2015;22(12):1255-65
pubmed: 26269147
Atherosclerosis. 2013 Dec;231(2):359-64
pubmed: 24267252
Hypertension. 2018 Nov;72(5):1060-1071
pubmed: 30354826
J Biomech Eng. 1993 Nov;115(4B):481-8
pubmed: 8302029
Am J Med. 2004 Feb 15;116(4):263-72
pubmed: 14969655
J Hypertens. 2015 Sep;33(9):1742-57; discussion 1757
pubmed: 26114836
Kidney Blood Press Res. 2010;33(4):304-12
pubmed: 20664284
Hypertension. 2005 Jul;46(1):200-4
pubmed: 15911742
Am J Kidney Dis. 2005 Mar;45(3):494-501
pubmed: 15754271
Atherosclerosis. 2015 Oct;242(2):461-8
pubmed: 26295798
J Atheroscler Thromb. 2006 Apr;13(2):101-7
pubmed: 16733298
J Atheroscler Thromb. 2011;18(1):49-55
pubmed: 21071883
Kidney Int. 2006 Jan;69(2):350-7
pubmed: 16408126
J Hypertens. 2017 Jan;35(1):98-104
pubmed: 27906838
Am J Physiol Renal Physiol. 2019 May 1;316(5):F898-F905
pubmed: 30810061
J Clin Hypertens (Greenwich). 2014 May;16(5):372-7
pubmed: 24716575
Semin Dial. 2010 Jul-Aug;23(4):415-21
pubmed: 20557489
Hypertens Res. 2014 Apr;37(4):253-390
pubmed: 24705419
BMC Cardiovasc Disord. 2016 Jan 13;16:9
pubmed: 26758197
J Am Soc Nephrol. 2009 Sep;20(9):2044-53
pubmed: 19608701
Arch Intern Med. 2008 Nov 10;168(20):2212-8
pubmed: 19001197
Am J Kidney Dis. 2010 Jul;56(1):32-8
pubmed: 20416999
J Am Soc Nephrol. 2006 Aug;17(8):2245-52
pubmed: 16837632
Hypertension. 2017 Oct;70(4):660-667
pubmed: 28784646

Auteurs

Seiji Itano (S)

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Yuichiro Yano (Y)

Department of Family Medicine and Community Health, Duke University, Durham, North Carolina, USA.

Hajime Nagasu (H)

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Hirofumi Tomiyama (H)

Department of Cardiology and Division of Preemptive Medicine for Vascular Damage, Tokyo Medical University, Tokyo, Japan.

Hiroshi Kanegae (H)

Genki Plaza Medical Center for Health Care, Tokyo, Japan.

Hirofumi Makino (H)

Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University, Okayama, Japan.

Yukihito Higashi (Y)

Division of Regeneration and Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

Yusuke Kobayashi (Y)

Center for Novel and Exploratory Clinical Trials (Y-NEXT), Yokohama City University Hospital, Yokohama, Japan.
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Yuji Sogawa (Y)

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Minoru Satoh (M)

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Kenji Suzuki (K)

Japan Health Promotion Foundation, Tokyo, Japan.

Raymond R Townsend (RR)

Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Matthew Budoff (M)

Department of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.

George Bakris (G)

American Heart Association Comprehensive Hypertension Center, Department of Medicine, Section of Endocrinology, Diabetes, and Metabolism, The University of Chicago Medicine, Chicago, Illinois, USA.

Naoki Kashihara (N)

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH